Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis

Tengda Li; Mingli Gu; Anmei Deng; Cheng Qian

doi:10.1186/s12935-020-01309-5

Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis

Cancer Cell Int. 2020 Jun 15:20:239. doi: 10.1186/s12935-020-01309-5. eCollection 2020.

Authors

Tengda Li¹, Mingli Gu², Anmei Deng³, Cheng Qian⁴

Affiliations

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020 China.
² Department of Laboratory Diagnosis, Changhai Hospital, The Second Military Medical University, Shanghai, 200433 China.
³ Changhai Hospital, The Second Military Medical University, Shanghai, 200433 China.
⁴ Department of Laboratory Medicine, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071 China.

Abstract

Background: The incidence and mortality of melanoma is increasing around the world. To deeply explain the mechanism insight into it, we conducted a systematic analysis to examine the levels of regulatory genes of the common RNA epigenetic modification-N6-methyladenosine (m⁶A) in patients with melanoma compared by the healthy.

Methods: We analyzed the expression of m⁶A Eraser, Writer, and Reader genes based on publicly available datasets on Oncomine and validated the results with a gene expression omnibus dataset. Hub genes were identified with Cytohubba and the frequency of copy number alterations was analyzed with the cBioPortal tool.

Results: The results revealed the up-regulation of YTHDF1 and HNRNPA2B1 in melanoma. Combining the two genes improved the efficacy in diagnosing melanoma by about 10% compared to each gene alone. Hub genes identified with four analysis methods were compared and the overlapping genes were selected. These genes were enriched in several gene ontology terms. Genes related to p53-signaling consisted of CDK2, CDK1, RRM2, CCNB1, and CHEK1. All five genes were positively correlated with either YTHDF1 or HNRNPA2B1, suggesting that both genes may affect m⁶A modification by the five genes, further up-regulating their expression and facilitate their roles in inhibiting p53 to suppress tumorigenesis. We also observed major mutations in YTHDF1 and HNRNPA2B1 that led to their amplification in melanoma. Significant differences were observed in the clinical characteristics of patients with altered and unaltered m⁶A regulatory genes such as tumor stage and treatment response.

Conclusions: We, for the first time, identified a combination of m⁶A regulatory genes to diagnose melanoma. We also analyzed m⁶A-related genes more comprehensively based on systematic complete data. We found that YTHDF1 and HNRNPA2B1 were altered in melanoma and might influence the development of the disease through signaling pathways such as p53.

Keywords: HNRNPA2B1; Melanoma; Systematic analysis; YTHDF1; m6A; p53.